Quick Answer
Alto Neuroscience, Inc. reported Stockholders Equity of $151.14 million for the year ending 2025.
- Alto Neuroscience, Inc. showed a decrease of -0.2% in Stockholders Equity from 2024 to 2025.
- This data is from Alto Neuroscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$45.23 million | Q2 2023: -$52.60 million | Q3 2023: -$61.10 million | Q1 2024: $193.10 million | Q2 2024: $179.78 million | Q3 2024: $165.05 million | Q1 2025: $139.10 million | Q2 2025: $123.41 million | Q3 2025: $111.56 million.
- Over the full 4 years of available data (2022 to 2025), Alto Neuroscience, Inc.'s Stockholders Equity has grown by 493.5%.
- Historical annual values: Fiscal year 2025: $151.14 million | Fiscal year 2024: $151.46 million | Fiscal year 2023: -$71.67 million | Fiscal year 2022: -$38.41 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: